

Supplementary Table 1. A total of 41 cytokines, chemokines and growth factors used in this study

Cytokines and ligands		Chemokines and ligands		Growth factors	
Full name	Abbreviation	Full name	Abbreviation	Full name	Abbreviation
Granulocyte-colony stimulating factor	G-CSF	Cutaneous T-cell-attracting chemokine	CTACK	Basic fibroblast growth factor	Basic FGF
Interleukin 1 α	IL-1 α	C-C Motif Chemokine Ligand 11	Eotaxin	Hepatocyte growth factor	HGF
Interleukin 1 β	IL-1 β	Growth-regulated oncogene α	GRO α	Platelet-derived growth factor-BB	PDGF-BB
Interleukin 10	IL-10	Interferon γ induced protein 10	IP-10	Stem Cell Growth Factor-beta	SCGF β
Interleukin 12 (p70)	IL-12 (p70)	Leukemia inhibitory factor	LIF	vascular endothelial growth factor	VEGF
Interleukin 13	IL-13	Monocyte chemotactic protein 1	MCP-1	β Nerve growth factor	β -NGF
Interleukin 15	IL-15	Migration inhibitory factor	MIF		
Interleukin 16	IL-16	Monokine induced by interferon γ	MIG		
Interleukin 17	IL-17	Macrophage inflammatory protein 1 β	MIP-1 β		
Interleukin 18	IL-18	C-C Motif Chemokine Ligand 5	RANTES		
Interleukin 1R α	IL-1R α	Stem cell factor	SCF		
Interleukin 2	IL-2	stromal cell-derived factor 1 α	SDF-1 α		
Interleukin 2R α	IL-2R α				
Interleukin 3	IL-3				
Interleukin 5	IL-5				
Interleukin 6	IL-6				
Interleukin 8	IL-8				
Interleukin 9	IL-9				
Tumor necrosis factor α	TNF α				
Tumor necrosis factor β	TNF β				
macrophage colony-stimulating factor	M-CSF				
TNF-Related Apoptosis Inducing Ligand	TRAIL				
Interferon γ	IFN γ				

Supplementary Table 2. The analysis of TNF α and IL-8 expression in all the patients

Groups	Cytokines	Screening group (n=39)			Validation group (n=81)		
		Median (range)		P-Value	Median (range)		P-Value
		<i>ICH (n=15)</i>	<i>non-ICH (n=24)</i>		<i>ICH (n=15)</i>	<i>non-ICH (n=24)</i>	
Low WBC count group	TNF α	32.48 (17.6-79.35)	23.41 (10.41-40.8)	0.047	12.15 (6-49.7)	4.64 (4-7)	<0.001
High WBC count group	IL-8	96.85 (73.07-2118.03)	75.37 (20.75-147.6)	0.208	51.15 (25.5-136)	13.5 (5-72.4)	0.002

Supplementary Table 3. Clinical characteristic of the remaining 81 APL patients

Characteristic	Low WBC count group (n=53)	High WBC count group (n=28)
	Median (range) / Number of patients	Median (range) / Number of patients
Age, y	35 (14-70)	36 (14-66)
Gender, N (%)		
Male	22 (41.51)	17 (60.71)
Female	31 (58.49)	11 (39.29)
Risk, N (%)		
Low	23 (43.4)	
Intermediate	30 (56.6)	
Leucocyte count, ×10⁹/L	2.5 (0.5-9.9)	35.17 (8.95-159.7)
Hemoglobin, g/L	84 (37-133)	88 (44-134)
Platelet count, ×10⁹/L	36 (2-104)	25 (7-71)
APTT, s	28.5 (18.4-38.2)	28.65 (22.1-40.8)
PT, s	12.9 (10.22-16.9)	15 (10.2-21.6)
INR	1.13 (0.89-1.7)	1.26 (0.86-1.79)
Fg, g/L	1.6 (0.6-5)	1 (0.4-5)
D-Dimer, mg/L	10.57 (0.1-45.1)	8.78 (0.11-40)
Lactic dehydrogenase, U/L	223 (103-2606)	460.5 (143-1982)
BM blast (%)	81 (15-96)	91.25 (78.5-98)
PB blast (%)	54 (1-95)	92 (56-97)

APTT, activated partial thromboplastin time; Fg, fibrinogen; LDH, lactic dehydrogenase; BM, bone marrow; PB, peripheral blood; PR, PML-RAR α